0001558370-20-013862 | 6-K | XBRL Viewer

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2020
Document And Entity Information Abstract
Entity Registrant Name	ProQR Therapeutics N.V.
Entity Central Index Key	0001612940
Document Type	6-K
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3

Condensed Consolidated Statement of Financial Position - EUR (€)	Sep. 30, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	€ 88,847,000	€ 111,950,000
Prepayments and other receivables	2,759,000	1,866,000
Social securities and other taxes	552,000	850,000
Total current assets	92,158,000	114,666,000
Property, plant and equipment	17,875,000	2,440,000
Investments in associates	159,000	429,000
Total assets	110,192,000	117,535,000
Equity
Equity attributable to owners of the Company	68,626,000	94,329,000
Non-controlling interests	(534,000)	(496,000)
Total equity	68,092,000	93,833,000
Current liabilities
Borrowings	949,000	343,000
Lease liabilities	1,308,000	508,000
Derivative financial instruments	1,092,000
Trade payables	291,000	445,000
Current income tax liability	0	64,000
Social securities and other taxes	155,000	108,000
Pension premiums		2,000
Deferred income	863,000	711,000
Other current liabilities	6,159,000	8,812,000
Total current liabilities	10,817,000	10,993,000
Borrowings	16,577,000	12,709,000
Lease liabilities	14,706,000
Total liabilities	42,100,000	23,702,000
Total equity and liabilities	€ 110,192,000	€ 117,535,000

Condensed Consolidated Statement of Profit or Loss and OCI - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Condensed Consolidated Statement of Profit or Loss and OCI
Other income	€ 251	€ 530	€ 9,188	€ 1,509
Research and development costs	(8,304)	(11,074)	(29,716)	(32,560)
General and administrative costs	(2,809)	(2,903)	(10,173)	(8,970)
Total operating costs	(11,113)	(13,977)	(39,889)	(41,530)
Operating result	(10,862)	(13,447)	(30,701)	(40,021)
Finance income and expense	(1,863)	1,375	(2,024)	1,339
Results related to financial liabilities measured at fair value through profit or loss	(305)		(305)
Results related to associates	(84)	(119)	(270)	579
Result before corporate income taxes	(13,114)	(12,191)	(33,300)	(38,103)
Income taxes	(75)		(86)	(64)
Result for the period	(13,189)	(12,191)	(33,386)	(38,167)
Other comprehensive income	(255)	147	(134)	121
Total comprehensive income (attributable to owners of the Company)	(13,444)	(12,044)	(33,520)	(38,046)
Result attributable to
Owners of the Company	(13,181)	(12,139)	(33,348)	(37,945)
Non-controlling interests	(8)	(52)	(38)	(222)
Result for the period	€ (13,189)	€ (12,191)	€ (33,386)	€ (38,167)
Share information
Weighted average number of shares outstanding	50,143,262	38,912,701	50,017,990	38,902,203
Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)
Basic loss per share	€ (0.26)	€ (0.31)	€ (0.67)	€ (0.98)
Diluted loss per share	€ (0.26)	€ (0.31)	€ (0.67)	€ (0.98)

Condensed Consolidated Statement of Changes in Equity - EUR (€) € in Thousands	Share capital	Share Premium [Member]	Equity Settled Employee Benefit Reserve	Option premium on convertible loan	Translation Reserve	Accumulated Deficit	Total	Non-controlling interests [Member]	Total
Balance at beginning of period at Dec. 31, 2018	€ 1,726	€ 235,744	€ 10,780		€ 108	€ (155,443)	€ 92,915	€ (230)	€ 92,685
Balance at beginning of period (in shares) at Dec. 31, 2018	43,149,987
Result for the period						(37,945)	(37,945)	(222)	(38,167)
Other comprehensive income					121		121		121
Recognition of share-based payments			4,614				4,614		4,614
Treasury shares transferred (in shares)	(40,259)
Shares options lapsed			(33)			33
Share options exercised		166	(115)			115	166		166
Share options exercised (in shares)	40,259
Balance at end of period at Sep. 30, 2019	€ 1,726	235,910	15,246		229	(193,240)	59,871	(452)	59,419
Balance at end of period (in shares) at Sep. 30, 2019	43,149,987
Balance at beginning of period at Dec. 31, 2019	€ 2,159	287,214	16,551		151	(211,746)	94,329	(496)	93,833
Balance at beginning of period (in shares) at Dec. 31, 2019	53,975,838
Result for the period						(33,348)	(33,348)	(38)	(33,386)
Other comprehensive income					(134)		(134)		(134)
Recognition of share-based payments	€ 2	283	6,218				6,503		6,503
Issue of ordinary shares	€ 2	270					272		272
Issue of ordinary shares (in shares)	100,902
Treasury shares transferred (in shares)	(299,615)
Recognition of equity component of convertible loan				€ 280			280		280
Shares options lapsed			(63)			63
Share options exercised		724	(466)			466	724		724
Share options exercised (in shares)	299,615
Balance at end of period at Sep. 30, 2020	€ 2,163	€ 288,491	€ 22,240	€ 280	€ 17	€ (244,565)	€ 68,626	€ (534)	€ 68,092
Balance at end of period (in shares) at Sep. 30, 2020	54,076,740

Consolidated Statement of Cash Flows - EUR (€)	3 Months Ended		9 Months Ended
Consolidated Statement of Cash Flows - EUR (€)	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Cash flows from operating activities
Net result	€ (13,189,000)	€ (12,191,000)	€ (33,386,000)	€ (38,167,000)
Adjustments for:
Depreciation	651,000	506,000	1,703,000	1,543,000
Share-based compensation	1,676,000	1,226,000	6,348,000	4,614,000
Other income			(8,423,000)
Financial income and expenses	1,863,000	(1,375,000)	2,024,000	(1,339,000)
Results related to associates	84,000	119,000	270,000	(579,000)
Results related to financial liabilities measured at fair value through profit or loss	305,000		305,000
Net foreign exchange gain / (loss)	(255,000)	148,000	(134,000)	122,000
Changes in working capital	(246,000)	2,718,000	(3,354,000)	1,744,000
Cash used in operations	(9,111,000)	(8,849,000)	(34,647,000)	(32,062,000)
Corporate income tax paid	(157,000)		(168,000)	(64,000)
Interest received	27,000	90,000	118,000	176,000
Interest paid	(569,000)	(13,000)	(607,000)	(64,000)
Net cash used in operating activities	(9,810,000)	(8,772,000)	(35,304,000)	(32,014,000)
Cash flow from investing activities
Purchases of property, plant and equipment	(264,000)	(32,000)	(806,000)	(341,000)
Net cash used in investing activities	(264,000)	(32,000)	(806,000)	(341,000)
Cash flow from financing activities
Proceeds from exercise of share options	12,000	2,000	724,000	166,000
Proceeds from borrowings			579,000
Proceeds from convertible loans	13,477,000		13,542,000	690,000
Repayment of lease liability	(235,000)	(290,000)	(542,000)	(861,000)
Net cash generated by/(used in) financing activities	13,254,000	(288,000)	14,303,000	(5,000)
Net increase/(decrease) in cash and cash equivalents	3,180,000	(9,092,000)	(21,807,000)	(32,360,000)
Currency effect cash and cash equivalents	(1,474,000)	1,420,000	(1,296,000)	1,572,000
Cash and cash equivalents, at beginning of the period	87,141,000	82,464,000	111,950,000	105,580,000
Cash and cash equivalents at the end of the period	€ 88,847,000	€ 74,792,000	€ 88,847,000	€ 74,792,000

General Information

9 Months Ended

Sep. 30, 2020

General Information

General Information

1. General information

ProQR Therapeutics N.V., or “ProQR” or the “Company”, is a development stage company domiciled in the Netherlands that primarily focuses on the development and commercialization of novel therapeutic medicines.

Since September 18, 2014, the Company’s ordinary shares are listed on the NASDAQ Global Market under ticker symbol PRQR.

The Company was incorporated in the Netherlands, on February 21, 2012 and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.

ProQR Therapeutics N.V. is the ultimate parent company of the following entities:

ProQR Therapeutics Holding B.V. (100%);

ProQR Therapeutics I B.V. (100%);

ProQR Therapeutics II B.V. (100%);

ProQR Therapeutics III B.V. (100%);

ProQR Therapeutics IV B.V. (100%);

ProQR Therapeutics VI B.V. (100%);

ProQR Therapeutics VII B.V. (100%);

ProQR Therapeutics VIII B.V. (100%);

ProQR Therapeutics IX B.V. (100%);

ProQR Therapeutics I Inc. (100%);

Amylon Therapeutics B.V. (80%);

Amylon Therapeutics Inc. (80%);

ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (“ESOP Foundation”) and has full control over this entity. ProQR Therapeutics N.V. holds a 20% minority shareholding in Wings Therapeutics Inc.

As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to “ProQR” or the “Company” refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.

Significant Accounting Policies	9 Months Ended
Significant Accounting Policies	Sep. 30, 2020
Significant Accounting Policies
Significant Accounting Policies	2. Significant Accounting Policies These condensed consolidated financial statements have been prepared in accordance with IAS 34 - Interim Financial Reporting. Certain information and disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2019. In the opinion of management, all adjustments, consisting of normal recurring nature, considered necessary for a fair presentation have been included in the condensed consolidated financial statements. The Company’s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors. The Company operates in one reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.

Adoption of new and revised International Financial Reporting Standards	9 Months Ended
	Sep. 30, 2020
Adoption of new and revised International Financial Reporting Standards
Adoption of new and revised International Financial Reporting Standards	3. Adoption of new and revised International Financial Reporting Standards The accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those applied in the preparation of the Company’s annual financial statements for the year ended December 31, 2019. New Standards and Interpretations, which became effective as of January 1, 2020, did not have a material impact on our condensed consolidated financial statements.

Critical Accounting Estimates and Judgments	9 Months Ended
Critical Accounting Estimates and Judgments	Sep. 30, 2020
Critical Accounting Estimates and Judgments
Critical Accounting Estimates and Judgments	4. Critical Accounting Estimates and Judgments In the application of the Company’s accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods. Research and development expenditures Research expenditures are currently not capitalized but are reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed. Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.

Cash and Cash Equivalents	9 Months Ended
Cash and Cash Equivalents	Sep. 30, 2020
Cash and Cash Equivalents.
Cash and Cash Equivalents	5. Cash and Cash Equivalents At September 30, 2020, the Company’s cash and equivalents were € 88,847,000 as compared to € 111,950,000 at December 31, 2019. The cash balances are held at banks with investment grade credit ratings. The cash at banks is at full disposal of the Company.

Property, plant and equipment	9 Months Ended
Property, plant and equipment	Sep. 30, 2020
Property, plant and equipment.
Property, plant and equipment	6. Property, plant and equipment At September 30, 2020 and December 31, 2019, property plant and equipment consisted of buildings and leasehold improvements, laboratory equipment and other assets. Buildings and leasehold improvements include a right-of-use asset relating to the lease of our Leiden office and laboratory space, with a carrying amount of € 15,923,000 at September 30, 2020 (December 31, 2019: € 606,000).

Current liabilities	9 Months Ended
Current liabilities	Sep. 30, 2020
Current liabilities
Current liabilities	7. Current liabilities At September 30, 2020 and December 31, 2019, the other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.

Borrowings

9 Months Ended

Sep. 30, 2020

Borrowings

Borrowings

8. Borrowings


	September 30,	December 31,
	2020	2019
	€ 1,000	€ 1,000
Innovation credit	2,771	7,191
Accrued interest on innovation credit	237	3,124
Convertible notes	14,140	2,473
Accrued interest on convertible notes	378	264

Total borrowings	17,526	13,052
Current portion	(949)	(343)
	16,577	12,709

On June 1, 2012, ProQR was awarded an Innovation credit by the Dutch government, through its agency RVO of the Ministry of Economic Affairs, for the Company’s cystic fibrosis program. Amounts were drawn under this facility in the course of the years 2013 through 2017. The credit covered 35% of the costs incurred in respect of the program up to € 5.0 million. The credit was interest-bearing at a rate of 10% per annum. In June 2020 ProQR received a final waiver of the full amount of the Innovation credit, including accumulated interest. Consequently, the carrying amount of € 8.4 million, including accumulated interest, was recognized in Other Income in the second quarter of 2020.

On December 10, 2018 ProQR was awarded an Innovation credit for the sepofarsen program for LCA 10. Amounts will be drawn under this facility from 2018 through 2021. The total credit of € 4.7 million will be used to conduct the Phase 2/3 clinical study for sepofarsen and to finance efforts to obtain regulatory and ethical market approval (NDA/MAA). The credit, including accrued interest of 10% per annum, is repayable depending on ProQR obtaining market approval for sepofarsen. An amount of € 2.8 million had been received as at September 30, 2020. Accumulated interest amounted to € 0.2 million as at September 30, 2020. The assets that are co-financed with the granted innovation credit are subject to a right of pledge for the benefit of RVO.

Convertible loans

On July 14, 2020, the Company entered into a convertible debt financing agreement with Pontifax Medison Debt Financing. Under the agreement, the Company will have access to up to $ 30 million in convertible debt financing in three tranches of $ 10 million each that will mature over a 54-month period and have an interest-only period of 24 months. One tranch of $ 10 million was drawn down at the end of the current reporting period and is recognized at amortized cost. A second close of the convertible debt financing agreement was completed on August 6, 2020 with Kreos Capital. Under the second agreement, the Company will have access to up to € 15 million in convertible debt financing in three tranches of € 5 million each that will mature over a 54-month period and have an interest-only period of 24 months. One tranche of € 5 million was drawn down at the end of the current reporting.

Pontifax and/or Kreos may elect to convert the outstanding loans into ProQR ordinary shares at any time prior to repayment at a fixed conversion price. ProQR also has the ability to convert the loans into its ordinary shares, at the same conversion price, if the Company’s stock price reaches a pre-determined threshold. In connection with the loan agreement, the Company issued to Pontifax and Kreos warrants to purchase up to an aggregate of 302,676 shares of its common stock at a fixed exercise price.

Pontifax’ conversion option and warrants are accounted for as embedded derivatives and are recognized separately from the host contract as financial liabilities at fair value through profit or loss. The host contract is recognized at amortized cost.

The Kreos loan is accounted for as a compound financial instrument. The liability component is recognized at amortized cost. The equity component is initially recognized at fair value as option premium on convertible loan and will not be subsequently remeasured. Kreos’ warrants are accounted for as embedded derivatives and are recognized as financial liabilities at fair value through profit or loss.

Convertible loans were issued to Amylon Therapeutics B.V. and are interest-bearing at an average rate of 8% per annum. They are convertible into a variable number of ordinary shares within 36 months at the option of the holder or the Company in case financing criteria are met. Any unconverted loans become payable on demand after 24 – 36 months in equal quarterly terms.

Lease Liabilities	9 Months Ended
Lease Liabilities	Sep. 30, 2020
Lease liabilities
Lease Liabilities	9. Lease liabilities At September 30, 2020 and December 31, 2019, lease liabilities consisted of the Company’s lease of office and laboratory facilities at Zernikedreef in Leiden, the Netherlands, where our headquarters and our laboratories are located. A new lease agreement was put in place on July 1, 2020 for a 10-year period, which may be extended for subsequent 5-year terms. The carrying amount of the right-of-use asset is disclosed under note 6 Property, plant & equipment.

Shareholders equity	9 Months Ended
Shareholders equity	Sep. 30, 2020
Shareholders equity
Shareholders' equity	10. Shareholders’ equity The authorized share capital of the Company amounting to € 7,200,000 consists of 90,000,000 ordinary shares and 90,000,000 preference shares with a par value of € 0.04 per share. At September 30, 2020, 54,076,740 ordinary shares were issued and fully paid in cash, of which 3,930,536 were held by the Company as treasury shares (December 31, 2019: 4,230,151). On November 7, 2018, the Company filed a shelf registration statement, which permitted the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 300,000,000 of its ordinary shares, warrants and/or units. In October 2019, the Company consummated an underwritten public offering of 10,454,545 ordinary shares at an issue price of $ 5.50 per share. The gross proceeds from this offering amounted to € 51,597,000 while the transaction costs amounted to € 3,047,000, resulting in net proceeds of € 48,550,000. In December 2019, the Company issued 371,306 shares in the aggregate amount of $3.5 million, at $9.43 (€8.51) per share to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, the second installment of the upfront payment in ordinary shares to the Company’s common stock was made to Ionis upon the dosing of the first patient in the phase 1/2 Aurora clinical trial for QR-1123. On March 31, 2020, the Company entered into a sales agreement, which permitted the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 75,000,000 of its ordinary shares that may be issued and sold in one or more at-the-market offerings with Citigroup Global Markets, Inc. and Cantor Fitzgerald & Co. In 2020, no shares were issued pursuant to this ATM facility. Translation reserve The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations. Share options The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options may be granted to employees, members of the Supervisory Board, members of the Management Board and consultants. The compensation expenses included in operating costs for this plan in the three month period ended September 30, 2020 were € 1,675,000 (2019: € 1,226,000), of which € 1,108,000 (2019: € 835,000) was recorded in general and administrative costs and € 567,000 (2019: € 391,000) was recorded in research and development costs.

Other income

9 Months Ended

Sep. 30, 2020

Other income

Other income

11. Other income


	Three month period
	ended September 30,
	2020	2019
	€ 1,000	€ 1,000

Grant income	212	518
Other income	39	12
	251	530

In June 2020 ProQR received a final waiver of the full amount of the Innovation credit for the Company’s cystic fibrosis program. Consequently, the carrying amount of €8.4 million, including accumulated interest, was recognized in Other Income in Q2 2020.

On February 9, 2018, the Company entered into a partnership agreement with Foundation Fighting Blindness (FFB), under which FFB has agreed to provide funding of $7.5 million for the pre-clinical and clinical development of QR‑421a for Usher syndrome type 2A targeting mutations in exon 13.

In addition, funding was received for the Huntington’s disease program.

Grants are recognized in other income in the same period in which the related R&D costs are recognized.

Research and development costs	9 Months Ended
Research and development costs	Sep. 30, 2020
Research and development costs
Research and Development Costs	12. Research and development costs Research and development costs amount to € 8,304,000 for the three month period ended September 30, 2020 (2019: € 11,074,000) and are comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs.

General and administrative costs	9 Months Ended
General and administrative costs	Sep. 30, 2020
General and administrative costs
General and administrative costs	13. General and administrative costs General and administrative costs amount to € 2,809,000 for the three month period ended September 30, 2020 (2019: € 2,903,000).

Results related to associates	9 Months Ended
Results related to associates	Sep. 30, 2020
Results related to associates
Results related to associates	14. Results related to associates The results related to associates for the three month period ended September 30, 2020 amount to € 84,000 (2019: € 119,000) and consist of our share of the net losses of Wings Therapeutics Inc.

Income taxes	9 Months Ended
Income taxes	Sep. 30, 2020
Income taxes
Income taxes	15. Income taxes The current income tax liability amounts to € nil at September 30, 2020 (December 31, 2019: € 64,000). No significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.

Events after balance sheet date	9 Months Ended
Events after balance sheet date	Sep. 30, 2020
Events after balance sheet date
Events after balance sheet date	16. Events after balance sheet date No significant events have occurred after the balance sheet date.

Borrowings (Tables)

9 Months Ended

Sep. 30, 2020

Borrowings

Schedule of borrowings


	September 30,	December 31,
	2020	2019
	€ 1,000	€ 1,000
Innovation credit	2,771	7,191
Accrued interest on innovation credit	237	3,124
Convertible notes	14,140	2,473
Accrued interest on convertible notes	378	264

Total borrowings	17,526	13,052
Current portion	(949)	(343)
	16,577	12,709

Other income (Tables)

9 Months Ended

Sep. 30, 2020

Other income

Other income


	Three month period
	ended September 30,
	2020	2019
	€ 1,000	€ 1,000

Grant income	212	518
Other income	39	12
	251	530

General Information (Details)	9 Months Ended
General Information (Details)	Sep. 30, 2020
ProQR Therapeutics Holding B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics I B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics II B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics III B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics IV B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics VI B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics VII B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics VIII B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
ProQR Therapeutics IX B.V. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Amylon Therapeutics B.V [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	80.00%
Amylon Therapeutics Inc [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	80.00%
ProQR Therapeutics I Inc. [Member]
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	100.00%
Wings Therapeutics Inc
Disclosure of subsidiaries [line items]
Proportion of ownership interest in subsidiary	20.00%

Significant Accounting Policies (Details)	9 Months Ended
Significant Accounting Policies (Details)	Sep. 30, 2020 segment
Significant Accounting Policies
Ifrs Number of Reportable Segments	1

Cash and Cash Equivalents (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Jun. 30, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Dec. 31, 2018
Cash and Cash Equivalents.
Cash and cash equivalents	€ 88,847	€ 87,141	€ 111,950	€ 74,792	€ 82,464	€ 105,580

Property, Plant and Equipment (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment
Property, plant and equipment	€ 17,875	€ 2,440
Building And Leasehold Improvements
Property, Plant and Equipment
Property, plant and equipment	€ 15,923	€ 606

Borrowings (Details) € in Thousands, $ in Millions				1 Months Ended	3 Months Ended	9 Months Ended
Borrowings (Details) € in Thousands, $ in Millions	Aug. 06, 2020 EUR (€) tranche	Jul. 14, 2020 USD ($) tranche shares	Jun. 01, 2012 EUR (€)	Jun. 30, 2020 EUR (€)	Sep. 30, 2020 EUR (€)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 EUR (€)	Sep. 30, 2019 EUR (€)	Dec. 31, 2019 EUR (€)	Dec. 10, 2018 EUR (€)
Disclosure of detailed information about borrowings [line items]
Total borrowings					€ 17,526		€ 17,526		€ 13,052
Current portion					(949)		(949)		(343)
Non Current portion					16,577		16,577		12,709
Proceeds from borrowings							579
Debt convertible					13,477		13,542	€ 690
Innovation credit
Disclosure of detailed information about borrowings [line items]
Total borrowings					2,771		2,771		7,191	€ 4,700
Accrued interest					237		237		3,124
Percentage of cost covered by the innovative credit			35.00%
Maximum initial borrowing base			€ 5,000
Interest rate (as percent)			10.00%
Total conditional waiver of debt				€ 8,400
Proceeds from borrowings							2,800
Convertible notes
Disclosure of detailed information about borrowings [line items]
Total borrowings					14,140		14,140		2,473
Accrued interest					€ 378		€ 378		€ 264
Interest rate (as percent)					8.00%		8.00%
Debt instrument convertible term						36 months	36 months
Convertible notes \| Minimum
Disclosure of detailed information about borrowings [line items]
Unconvertible debt maturity						P24M	P24M
Convertible notes \| Maximum
Disclosure of detailed information about borrowings [line items]
Unconvertible debt maturity						P36M	P36M
Convertible Debt
Disclosure of detailed information about borrowings [line items]
Warrants issued to purchase common stock \| shares		302,676
Convertible Debt Pontifax Medison Debt Financing
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity \| $		$ 30
Number of tranches \| tranche		3
Maximum borrowing capacity per tranche \| $		$ 10
Term of debt		54 months
Debt, interest only payment term		24 months
Debt convertible \| $						$ 10
Convertible Debt Kreos Capital Debt Financing
Disclosure of detailed information about borrowings [line items]
Maximum borrowing capacity	€ 15,000
Number of tranches \| tranche	3
Maximum borrowing capacity per tranche	€ 5,000
Term of debt	54 months
Debt, interest only payment term	24 months
Debt convertible							€ 5,000

Lease Liabilities (Details)	Jul. 01, 2020
Lease liabilities
Lease agreement period	10 years
Lease renewal term	5 years

Shareholders equity - Share capital (Details)	1 Months Ended		9 Months Ended
Shareholders equity - Share capital (Details)	Oct. 31, 2019 $ / shares shares	Oct. 31, 2019 EUR (€) shares	Sep. 30, 2020 EUR (€) € / shares shares	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($) $ / shares shares	Dec. 31, 2019 € / shares	Nov. 07, 2018 USD ($)
Shareholders' Equity
Authorized share capital \| €			€ 7,200,000
Par value per share \| € / shares			€ 0.04
Shares were issued and fully paid in cash	10,454,545	10,454,545
Price per share \| $ / shares	$ 5.50
Net proceeds from issuance of shares \| €		€ 48,550,000
Transaction costs of public offering \| €		3,047,000
Gross proceeds from issuance of shares \| €		€ 51,597,000
Shares issued in the period \| €			€ 272,000
Ordinary
Shareholders' Equity
Maximum aggregate offering of ordinary shares \| $							$ 300,000,000
Number of shares authorised			90,000,000
Shares were issued and fully paid in cash			54,076,740
Treasury shares			3,930,536		4,230,151
Preferred
Shareholders' Equity
Number of shares authorised			90,000,000
Market offering program \| Ordinary
Shareholders' Equity
Number of shares issued			0
Maximum aggregate offering of ordinary shares \| $				$ 75,000,000
Ionis Pharmaceuticals, Inc \| Worldwide License Agreement
Shareholders' Equity
Number of shares issued					371,306
Maximum aggregate offering of ordinary shares \| $					$ 3,500,000
Share price \| (per share)					$ 9.43	€ 8.51

Shareholders equity - Share options (Details) - EUR (€)	3 Months Ended
Shareholders equity - Share options (Details) - EUR (€)	Sep. 30, 2020	Sep. 30, 2019
Shareholders equity
Compensation expenses	€ 1,675,000	€ 1,226,000
Compensation expenses recorded in general and administrative costs	1,108,000	835,000
Compensation expenses recorded in research and development costs	€ 567,000	€ 391,000

Other income (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
Other income (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Other income
Grant income	€ 212	€ 518
Other income	39	12
Total other income	€ 251	€ 530	€ 9,188	€ 1,509

Other income - Narrative (Details) € in Millions, $ in Millions		1 Months Ended
	Feb. 09, 2018 USD ($)	Jun. 30, 2020 EUR (€)
Clinical support agreement \| Foundation Fighting Blindness
Other Income [Line Items]
Contribution received to support clinical development \| $	$ 7.5
Innovation credit
Other Income [Line Items]
Total conditional waiver of debt \| €		€ 8.4

Research and development costs (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Research and development costs
Research and development costs	€ 8,304	€ 11,074	€ 29,716	€ 32,560

General and administrative costs (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
General and administrative costs
General and administrative expense	€ 2,809	€ 2,903	€ 10,173	€ 8,970

Results related to associates (Details) - EUR (€)	3 Months Ended
Results related to associates (Details) - EUR (€)	Sep. 30, 2020	Sep. 30, 2019
Wings Therapeutics Inc
Disclosure of associates [line items]
Loss on share of profits of associates	€ 84,000	€ 119,000

Income Taxes (Details) - EUR (€)	Sep. 30, 2020	Dec. 31, 2019
Income taxes
Current income tax liability	€ 0	€ 64,000